Evidence map›Paper›PMID 30947869›Full record

ReviewClinics in liver disease2019

The Liver and Celiac Disease.

Alberto Rubio-Tapia, Joseph A Murray

Open access · greenAbstract readReview
In one paragraph

Review in Clinics in liver disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 3 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Review
  5. Non-Diarrheal Celiac Disease in Iraq: A Multicenter study.Middle East journal of digestive diseases · 2025
    Article
  6. Liver Involvement in Celiac Disease and Immune-Mediated Diseases of the Small Bowel.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Review
  7. Article
  8. Coeliac disease and chronic liver disease: a double-face issue.The Lancet regional health. Europe · 2025
    Article
  9. Review
  10. Fatty liver and celiac disease: Why worry?World journal of hepatology · 2023
    Review
  11. Article
  12. Review article: Follow-up of coeliac disease.Alimentary pharmacology & therapeutics · 2022
    Review
  13. The global burden of coeliac disease: opportunities and challenges.Nature reviews. Gastroenterology & hepatology · 2022
    Review
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Alberto Rubio-TapiaDivision of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55905, USA.
Joseph A MurrayDivision of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55905, USA. Electronic address: murray.joseph@mayo.edu.
Mayo Clinic · US

Funding

Latiglutenase as a Treatment for Celiac DiseaseR33AT009637 · NCCIH · IMMUNOGENICS, LLC · PI MURRAY, JOSEPH A, SYAGE, JACK A. · 2017 to 2020
$1.5M
NCCIH NIH HHS R33 AT009637
6 · The paper itself

Abstract

Celiac disease is a multisystem disorder. Celiac hepatitis characterized by gluten-responsive mild elevation of transaminases is the more common liver manifestation of celiac disease. Celiac disease may also be associated or coexist with other chronic liver disorders. Shared genetic risk and increased intestinal permeability have been suggested to be the most relevant events in the pathogenesis of liver injury in celiac disease. The aim of this article is to review the full spectrum of liver disorders in patients with celiac disease.

Indexed as

Celiac DiseaseDiet, Gluten-FreeHumansLiverLiver DiseasesLiver Function TestsAlanine aminotransferaseCirrhosisHepatitis

Identifiers

PMID30947869
PMCPMC6588186
OpenAlexW2918622486

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.